TherapeuticsMD (TXMD) Liabilities and Shareholders Equity (2010 - 2026)

TherapeuticsMD has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $37.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 1.71% year-over-year to $37.6 million; the trailing twelve-month figure through Mar 2026 stood at $152.4 million (down 2.76% YoY), and the FY2025 full-year result was $37.7 million, down 3.0% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $37.6 million, roughly flat from $37.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $146.2 million in Q2 2022, with the low at $37.6 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $62.5 million across 5 years, with a median of $42.1 million in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 63.28% — and 2026, when it fell 1.71%.
• TherapeuticsMD's Liabilities and Shareholders Equity stood at $90.5 million in 2022, then tumbled by 52.12% to $43.3 million in 2023, then retreated by 10.36% to $38.8 million in 2024, then dropped by 3.0% to $37.7 million in 2025, then declined by 0.2% to $37.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $37.6 million (Q1 2026), $37.7 million (Q4 2025), and $38.7 million (Q3 2025), per Business Quant data.